{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-25-000068","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.219907+00:00","generated_at":"2026-05-17T00:34:45.997934+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Supernus Q3 rev $192M, up 9%; growth products up 52%; ONAPGO supply constraint","bullets":["Total revenues $192.1M (+9% YoY); combined growth product sales $149.2M (+52%).","Qelbree net sales $81.4M (+31% YoY); GOCOVRI $40.8M (+15% YoY).","ONAPGO net sales $6.8M in first full quarter; supply constraint pauses new patient starts.","ZURZUVAE collab revenue $20.2M (post Sage acquisition); Q3 U.S. sales up ~150% YoY.","Full-year 2025 revenue guidance raised; cash $281.2M at Sep 30, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-25-000068","json":"https://secwatch.observer/filing/0001356576-25-000068.json","markdown":"https://secwatch.observer/filing/0001356576-25-000068.md","text":"https://secwatch.observer/filing/0001356576-25-000068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657625000068/0001356576-25-000068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657625000068/supn-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:34:45.997934+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}